Nasopharyngeal carriage, antibiotic susceptibility and serotyping of Streptococcus pneumoniae and Haemophilus influenzae in children attending day care centers;Portage nasopharyngé, sensibilités et sérotypes de

Medecine et Maladies Infectieuses

Volumn 41, Issue 6, 2011, Pages 307-317

  Chavanet, P ^a   Atale, A ^a   Mahy, S ^a   Neuwirth, C ^a   Varon, E ^b   Dabernat, H ^c   Portier, H ^a  

^a DIJON UNIVERSITY HOSPITAL   (France)

^b Section of Radiology   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Haemophilus influenzae; Nasal carriage; Pneumococcus; Resistance; Serotype 19A; Vaccination

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM; CEFOTAXIME; ERYTHROMYCIN; PNEUMOCOCCUS VACCINE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM CULTURE; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE; HOSPITALIZATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; NOSE SMEAR; PRESCHOOL CHILD; PROTEIN BINDING; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

AGE FACTORS; ANTI-BACTERIAL AGENTS; CARRIER STATE; CHILD DAY CARE CENTERS; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DISEASE RESERVOIRS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; FRANCE; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS VACCINES; HOSPITALIZATION; HUMANS; INFANT; MALE; NASOPHARYNX; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PREVALENCE; PROSPECTIVE STUDIES; QUESTIONNAIRES; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 79958164748     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2011.02.001     Document Type: Article

References (56)

1. Raymond J., Cohen R., Moulin F., Gendrel D., Berche P. Facteurs influençant le portage de Streptococcus pneumoniae. Med Mal Infect 2002, 32(Suppl. 1):13-20.
2. Gray B.M., Converse G.M., Dillon H.C. Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24months of life. J Infect Dis 1980, 142:923-933.
3. Howard A.J., Dunkin K.T., Millar G.W. Nasopharyngeal carriage and antibiotic resistance of Haemophilus influenzae in healthy children. Epidemiol Infect 1988, 100:193-203.
4. Kouchner B. Plan national pour préserver l'efficacité des antibiotiques. http://www.santé.gouv.fr/htm/actu/antibio/index.htm 2001.
5. Morris S.K., Moss W.J., Halsey N. Haemophilus influenzae type b conjugate vaccine use and effectiveness. Lancet Infect Dis 2008, 8:435-443.
6. Watt J.P., Wolfson L.J., O'Brien K.L., et al. Burden of disease caused by Haemophilus influenzae type b in children younger than 5years: global estimates. Lancet 2009, 374:903-911.
7. Le réseau Epibac. Surveillance des infections invasives à Haemophilus influenzae, Listeria monocytogenes, Neisseria meningitidis, Streptococcus pneumoniae. Streptococcus agalactiae (B) et Streptococcus pyogenes (A) en France métropolitaine. Bulletin épidémiologique hebdomadaire ; http://www.invs.sante.fr/surveillance/epibac/index.htm.
8. Lepoutre A, Varon E, Georges S, Gutmann L, Lévy-Bruhl D and et les microbiologistes du réseau Epibac et du réseau des Observatoires régionaux du pneumocoque. Impact de la vaccination par le vaccin pneumococcique conjugué heptavalent sur l'incidence des infections invasives à pneumocoque en France. Bulletin épidémiologique hebdomadaire ; http://www.invs.sante.fr/presse/2008/le_point_sur/vaccination_pneumo_180108/index.html.
9. Whitney C.G., Farley M.M., Hadler J., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348:1737-1746.
10. Black S., Shinefield H., Fireman B., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000, 19:187-195.
11. Eskola J., Kilpi T., Palmu A., et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001, 344:403-409.
12. O'Brien K.L., Wolfson L.J., Watt J.P., et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5years: global estimates. Lancet 2009, 374:893-902.
13. Grijalva C.G., Nuorti J.P., Arbogast P.G., Martin S.W., Edwards K.M., Griffin M.R. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007, 369:1179-1186.
14. De Wals P., Robin E., Fortin E., Thibeault R., Ouakki M., Douville-Fradet M. Pneumonia after implementation of the pneumococcal conjugate vaccine program in the province of Quebec. Canada. Pediatr Infect Dis J 2008, 27:963-968.
15. Guevara M., Barricarte A., Gil-Setas A., et al. Changing epidemiology of invasive pneumococcal disease following increased coverage with the heptavalent conjugate vaccine in Navarre, Spain. Clin Microbiol Infect 2009, 15(11):1013-1019.
16. Kellner J.D., Vanderkooi O.G., MacDonald J., Church D.L., Tyrrell G.J., Scheifele D.W. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis 2009, 49:205-212.
17. Lacapa R., Bliss S.J., Larzelere-Hinton F., et al. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine. Clin Infect Dis 2008, 47:476-484.
18. Torzillo P.J., Morey F., Gratten M., Murphy D., Matters R., Dixon J. Changing epidemiology of invasive pneumococcal disease in central Australia prior to conjugate vaccine: a 16-year study. Vaccine 2007, 25:2375-2378.
19. Kyaw M.H., Lynfield R., Schaffner W., et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006, 354:1455-1463.
20. Cohen R, Levy C, Bonnet E, et al. Dynamic of pneumococcal nasopharyngeal carriage in children with acute otitis media following PCV7 introduction in France. Vaccine 2009;28(37):6114-21.
21. Fenoll A., Granizo J.J., Aguilar L., et al. Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J Clin Microbiol 2009, 47:1012-1020.
22. Millar E.V., O'Brien K.L., Watt J.P., et al. Effect of community-wide conjugate pneumococcal vaccine use in infancy on nasopharyngeal carriage through 3years of age: a cross-sectional study in a high-risk population. Clin Infect Dis 2006, 43:8-15.
23. O'Brien K.L., Millar E.V., Zell E.R., et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J Infect Dis 2007, 196:1211-1220.
24. Beall B., McEllistrem M.C., Gertz R.E., et al. Pre- and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002. J Clin Microbiol 2006, 44:999-1017.
25. Albrich W.C., Baughman W., Schmotzer B., Farley M.M. Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine. Clin Infect Dis 2007, 44:1569-1576.
26. Munoz-Almagro C., Jordan I., Gene A., Latorre C., Garcia-Garcia J.J., Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis 2008, 46:174-182.
27. Halasa N.B., Shankar S.M., Talbot T.R., et al. Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis 2007, 44:1428-1433.
28. Barricarte A., Castilla J., Gil-Setas A., et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine: a population-based case-control study. Clin Infect Dis 2007, 44:1436-1441.
29. Calbo E., Diaz A., Canadell E., et al. Invasive pneumococcal disease among children in a health district of Barcelona: early impact of pneumococcal conjugate vaccine. Clin Microbiol Infect 2006, 12:867-872.
30. Dagan R., Givon-Lavi N., Leibovitz E., Greenberg D., Porat N. Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population. J Infect Dis 2009, 199:776-785.
31. Hsieh Y.C., Lin P.Y., Chiu C.H., et al. National survey of invasive pneumococcal diseases in Taiwan under partial PCV7 vaccination in 2007: emergence of serotype 19A with high invasive potential. Vaccine 2009, 27:5513-5518.
32. Leach A.J., Morris P.S., McCallum G.B., et al. Emerging pneumococcal carriage serotypes in a high-risk population receiving universal 7-valent pneumococcal conjugate vaccine and 23-valent polysaccharide vaccine since 2001. BMC Infect Dis 2009, 9:121.
33. Lipsitch M., O'Neill K., Cordy D., et al. Strain characteristics of Streptococcus pneumoniae carriage and invasive disease isolates during a cluster-randomized clinical trial of the 7-valent pneumococcal conjugate vaccine. J Infect Dis 2007, 196:1221-1227.
34. Hicks L.A., Harrison L.H., Flannery B., et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007, 196:1346-1354.
35. Dalle F., Leroy J., Pechinot A., et al. Etude du portage nasopharyngé de Streptococcus pneumoniae et de Haemophilus influenzae et de leur sensibilité aux antibiotiques chez les enfants fréquentant des crèches collectives. Med Mal Infect 2000, 30:510-514.
36. Avis du Conseil supérieur d'hygiène publique de France. Calendrier vaccinal 2006 et autres avis du Conseil supérieur d'hygiène publique de France relatifs à la vaccination. Bulletin épidémiologique hebdomadaire 2006;29-30.
37. Société Française de Microbiologie. Les recommandations 2009 du CASFM. www.sfm.asso.fr 2009.
38. Kilian M. A taxonomic study of the genus Haemophilus, with the proposal of a new species. J Gen Microbiol 1976, 93:9-62.
39. Dabernat H., Delmas C., Seguy M., et al. Diversity of beta-lactam resistance-conferring amino acid substitutions in penicillin-binding protein 3 of Haemophilus influenzae. Antimicrob Agents Chemother 2002, 46:2208-2218.
40. Kaczmarek F.S., Gootz T.D., Dib-Hajj F., Shang W., Hallowell S., Cronan M. Genetic and molecular characterization of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae with unusually high resistance to ampicillin. Antimicrob Agents Chemother 2004, 48:1630-1639.
41. Sabuncu E., David J., Bernede-Bauduin C., et al. Significant reduction of antibiotic use in the community after a nationwide campaign in France, 2002-2007. PLoS Med 2009, 6:e1000084.
42. Seppala H., Klaukka T., Vuopio-Varkila J., et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 1997, 337:441-446.
43. Austin D.J., Kakehashi M., Anderson R.M. The transmission dynamics of antibiotic-resistant bacteria: the relationship between resistance in commensal organisms and antibiotic consumption. Proc Biol Sci 1997, 264:1629-1638.
44. Austin D.J., Kristinsson K.G., Anderson R.M. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc Natl Acad Sci U S A 1999, 96:1152-1156.
45. Ubukata K., Shibasaki Y., Yamamoto K., et al. Association of amino acid substitutions in penicillin-binding protein 3 with beta-lactam resistance in beta-lactamase-negative ampicillin-resistant Haemophilus influenzae. Antimicrob Agents Chemother 2001, 45:1693-1699.
46. Dagan R., Givon-Lavi N., Zamir O., et al. Reduction of nasopharyngeal carriage of Streptococcus pneumoniae after administration of a 9-valent pneumococcal conjugate vaccine to toddlers attending day care centers. J Infect Dis 2002, 185:927-936.
47. Cohen R., Levy C., de La Rocque F., et al. Impact of pneumococcal conjugate vaccine and of reduction of antibiotic use on nasopharyngeal carriage of nonsusceptible pneumococci in children with acute otitis media. Pediatr Infect Dis J 2006, 25:1001-1007.
48. Bekri H., Cohen R., Varon E., et al. Streptococcus pneumoniae serotypes involved in children with pleural empyemas in France. Arch Pediatr 2007, 14:239-243.
49. Mahjoub-Messai F., Doit C., Koeck J.L., et al. Population snapshot of Streptococcus pneumoniae serotype 19A isolates before and after introduction of seven-valent pneumococcal Vaccination for French children. J Clin Microbiol 2009, 47:837-840.
50. Dortet L., Ploy M.C., Poyart C., Raymond J. Emergence of Streptococcus pneumoniae of serotype 19A in France: molecular capsular serotyping, antimicrobial susceptibilities, and epidemiology. Diagn Microbiol Infect Dis 2009, 65:49-57.
51. Bingen E., Levy C., Varon E., et al. Pneumococcal meningitis in the era of pneumococcal conjugate vaccine implementation. Eur J Clin Microbiol Infect Dis 2008, 27:191-199.
52. Pai R., Gertz R.E., Whitney C.G., Beall B. Clonal association between Streptococcus pneumoniae serotype 23A, circulating within the United States, and an internationally dispersed clone of serotype 23F. J Clin Microbiol 2005, 43:5440-5444.
53. Whitney C.G., Pilishvili T., Farley M.M., et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006, 368:1495-1502.
54. Xu Q., Pichichero M.E., Casey J.R., Zeng M. Novel type of Streptococcus pneumoniae causing multidrug-resistant acute otitis media in children. Emerg Infect Dis 2009, 15:547-551.
55. Hsu H.E., Shutt K.A., Moore M.R., et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 2009, 360:244-256.
56. Varon E. http://www.onerba.org/fr/centre-doc/2009.